Using county-level Surveillance, Epidemiology, and End Results data from 2017 to 2021 (excluding 2020), we calculated Luminal A, Luminal B, HER2-enriched, and triple-negative breast cancer (TNBC) incidence rates. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.